Literature DB >> 11323675

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

V Shankaran1, H Ikeda, A T Bruce, J M White, P E Swanson, L J Old, R D Schreiber.   

Abstract

Lymphocytes were originally thought to form the basis of a 'cancer immunosurveillance' process that protects immunocompetent hosts against primary tumour development, but this idea was largely abandoned when no differences in primary tumour development were found between athymic nude mice and syngeneic wild-type mice. However, subsequent observations that nude mice do not completely lack functional T cells and that two components of the immune system-IFNgamma and perforin-help to prevent tumour formation in mice have led to renewed interest in a tumour-suppressor role for the immune response. Here we show that lymphocytes and IFNgamma collaborate to protect against development of carcinogen-induced sarcomas and spontaneous epithelial carcinomas and also to select for tumour cells with reduced immunogenicity. The immune response thus functions as an effective extrinsic tumour-suppressor system. However, this process also leads to the immunoselection of tumour cells that are more capable of surviving in an immunocompetent host, which explains the apparent paradox of tumour formation in immunologically intact individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11323675     DOI: 10.1038/35074122

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  875 in total

1.  Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery.

Authors:  W Asavaroengchai; Y Kotera; J J Mulé
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

2.  NF-κB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression.

Authors:  Feiyan Liu; Kankana Bardhan; Dafeng Yang; Muthusamy Thangaraju; Vadivel Ganapathy; Jennifer L Waller; Georgia B Liles; Jeffrey R Lee; Kebin Liu
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

Review 3.  The immunological synapse.

Authors:  Michael L Dustin
Journal:  Cancer Immunol Res       Date:  2014-11       Impact factor: 11.151

4.  T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells.

Authors:  Madhav V Dhodapkar; Joseph Krasovsky; Kara Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 5.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

6.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

Review 7.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

8.  Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

Authors:  Yu Jerry Zhou; Michelle Nicole Messmer; Robert Julian Binder
Journal:  Cancer Immunol Res       Date:  2013-12-31       Impact factor: 11.151

9.  Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies.

Authors:  Mariana Rodríguez Zubieta; David Furman; Marcela Barrio; Alicia Inés Bravo; Enzo Domenichini; José Mordoh
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

10.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.